Pages that link to "Q37831537"
Jump to navigation
Jump to search
The following pages link to Searching for synthetic lethality in cancer (Q37831537):
Displaying 50 items.
- Molecular biology of lung cancer: clinical implications (Q24610335) (← links)
- Repair of strand breaks by homologous recombination (Q27012688) (← links)
- Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro (Q27853018) (← links)
- Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic (Q28071541) (← links)
- Synthetic lethality in lung cancer and translation to clinical therapies (Q28072904) (← links)
- Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways (Q28533401) (← links)
- Regularized Machine Learning in the Genetic Prediction of Complex Traits (Q30346987) (← links)
- Realizing the promise of cancer predisposition genes (Q30743260) (← links)
- Update: the status of clinical trials with kinase inhibitors in thyroid cancer (Q33570056) (← links)
- Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma (Q33895858) (← links)
- Chemical genetics (Q33896011) (← links)
- Cancer. Taking a back door to target Myc. (Q34248946) (← links)
- Predicting drug-target interactions through integrative analysis of chemogenetic assays in yeast (Q34591150) (← links)
- Stimulation of oligonucleotide-directed gene correction by Redβ expression and MSH2 depletion in human HT1080 cells (Q35039019) (← links)
- Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines (Q35239892) (← links)
- Autoimmune response to PARP and BRCA1/BRCA2 in cancer (Q35793861) (← links)
- Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways (Q35837949) (← links)
- A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1. (Q35881172) (← links)
- Collateral sensitivity as a strategy against cancer multidrug resistance (Q35946556) (← links)
- Mutability and mutational spectrum of chromosome transmission fidelity genes (Q35954461) (← links)
- Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils (Q36038823) (← links)
- Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screens (Q36353967) (← links)
- XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance (Q36376707) (← links)
- Saccharomyces cerevisiae genetics predicts candidate therapeutic genetic interactions at the mammalian replication fork (Q36588976) (← links)
- Back to the Future: Mechanism-Based, Mutation-Specific Combination Chemoprevention with a Synthetic Lethality Approach (Q36616621) (← links)
- Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase (Q37223362) (← links)
- New developments in the treatment of ovarian cancer--future perspectives (Q37332487) (← links)
- Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors (Q37696682) (← links)
- A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer (Q37724940) (← links)
- Functional drug-gene interactions in lung cancer. (Q37999073) (← links)
- Deubiquitylating enzymes and DNA damage response pathways (Q38109871) (← links)
- The impact of germline mutations on targeted therapy (Q38151546) (← links)
- Therapeutic targeting of tumor suppressor genes (Q38306663) (← links)
- Therapeutic opportunities within the DNA damage response (Q38364665) (← links)
- Cell line name recognition in support of the identification of synthetic lethality in cancer from text (Q38402628) (← links)
- Antinuclear antibodies defining autoimmunity pathways (Q38643832) (← links)
- Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations. (Q38668684) (← links)
- Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells (Q38676328) (← links)
- Acoustic Liquid Handling for Rapid siRNA Transfection Optimization. (Q38880931) (← links)
- Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells (Q38986400) (← links)
- The cytotoxic and growth inhibitory effects of palladium(II) complexes on MDA-MB-435 cells (Q39368536) (← links)
- CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer (Q41156013) (← links)
- Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation (Q47302451) (← links)
- Cancer research: past, present and future. (Q48591667) (← links)
- Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer (Q49734875) (← links)
- Precision Oncology: The Road Ahead. (Q50195535) (← links)
- New insights and clinical advancements in cellular oncology. (Q53128619) (← links)
- Harnessing synthetic lethality to predict the response to cancer treatment. (Q55384044) (← links)
- Synthetic Lethality and Cancer - Penetrance as the Major Barrier (Q57190621) (← links)
- Distinct cellular responses to replication stress leading to apoptosis or senescence (Q64117251) (← links)